Amgen's Vectibix wins expanded colorectal cancer indications in Europe
This article was originally published in Scrip
Executive Summary
Amgen has won the European Commission's blessing to market the firm's anti-epidermal growth factor receptor (EGFR) inhibitor Vectibix (panitumumab) in the European Union for the expanded indications of treating patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line therapy in combination with FOLFOX (folinic acid, fluorouracil and oxaliplatin) and as a second-line treatment in combination with FOLFIRI (fololinic acid, fluorouracil and irinotecan) in patients who have received first-line fluoropyrimidine-based chemotherapy, excluding irinotecan.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.